In Re: Amitiza, No. 21-11057-MJJ, (D. Mass. Jan. 27, 2025)[1]

Factual Background

In 2004, Sucampo Pharmaceuticals, Inc. (“Sucampo”) entered into a marketing agreement with Takeda Pharmaceutical Company Limited, Takeda Pharmaceuticals U.S.A., Inc., and Takeda Pharmaceuticals America, Inc. (collectively, “Takeda”). The marketing agreement included a 16-year exclusive licensing arrangement for certain drugs, which came to include…